Recent Updates
Recently added Catalysts
AGEN Positive Sentiment

Samenvatting: Armenië verleent eerste vergunningen om Agenus’ BOT+BAL ten behoeve van eerder behandeld MSS gemetastaseerd colorectaal carcinoom in de handel te brengen

Thursday, October 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agenus Inc. has announced that the Ministry of Health of Armenia has granted permissions to market Botvymo® (botensilimab, BOT) and Evamplix® (balstilimab, BAL). Both products are approved for use in combination for the treatment of adult patients with microsatellite stable metastatic colorectal carcinoma (mCRC). This approval represents a significant advancement for Agenus in the immuno-oncology field.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agenus receives market approval in Armenia.
  • BOT and BAL are now available for mCRC treatment.
  • This marks a significant milestone for Agenus.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+121%
120-day peak, hindsight
Typical move
3.1%
average across 3 past catalysts
Cash runway
~0 mo
High dilution risk
Lead asset
Botensilimab
Phase 2 · Early Rectal Cancer

Full Press Release Details

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), een leider op gebied van innovatie in immuno-oncologie, maakte vandaag bekend dat het Ministerie van Gezondheid van de Republiek Armenië toestemmingen heeft verleend om Botvymo® (botensilimab, BOT) en Evamplix® (balstilimab, BAL) op de markt te brengen, allebei goedgekeurd voor gebruik in combinatie met de andere voor de behandeling van volwassen patiënten met MSS (microsatelliet stabiel) gemetastaseerd colorectaal carcinoom (mCRC)

Frequently Asked Questions

What approvals did Agenus receive in Armenia?

Agenus received permissions to market Botvymo® (BOT) and Evamplix® (BAL).

What is the indication for BOT and BAL?

Both products are approved for treating adult patients with MSS mCRC.

What is the significance of this approval?

This approval marks a significant milestone for Agenus in immuno-oncology.

ShareAdd on Google
Tags: AGEN Agenus BOT BAL mCRC Armenia
Last updated: Oct 8, 2026

Biotech snapshot

Cash runway
$19M liquidity · $10M/mo burn
~0 mo
High dilution risk
Lead asset
BotensilimabPhase 2
Early Rectal Cancer →

Catalyst track record

+121%
best trade around AGEN's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for AGEN.

See every catalyst's timing & PoA →